Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 2/2017

01-02-2017 | Meeting Report

The fifteenth International Conference on Progress in Vaccination against Cancer (PIVAC-15), 6–8 October 2015, Tübingen, Germany: looking back on 15 years of progress

Authors: Christopher Shipp, Graham Pawelec

Published in: Cancer Immunology, Immunotherapy | Issue 2/2017

Login to get access

Excerpt

PIVAC-15, held 6–8 October 2015 in Tübingen, Germany, marked the 15th anniversary of the PIVAC conference series (http://​www.​tati-group.​de/​pivac), held every year since PIVAC-1 in 2001 in Cambridge, UK. Prominent themes covered during the 2015 PIVAC meeting included therapies which can be used to modulate the immune system or reduce tumour-induced immune suppression, the selection of more appropriate immunotherapy targets, and methods that can be used to improve antigen presentation. In the context of 15 years of “Progress in Vaccination against Cancer”, speakers were asked to consider vaccination in the era of immunomodulatory antibody therapies that have so revolutionised the treatment of several types of cancer over the last few years. …
Metadata
Title
The fifteenth International Conference on Progress in Vaccination against Cancer (PIVAC-15), 6–8 October 2015, Tübingen, Germany: looking back on 15 years of progress
Authors
Christopher Shipp
Graham Pawelec
Publication date
01-02-2017
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 2/2017
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-016-1888-4

Other articles of this Issue 2/2017

Cancer Immunology, Immunotherapy 2/2017 Go to the issue

Original Article

Elevated regulatory T cells, surface and intracellular CTLA-4 expression and interleukin-17 in the lung cancer microenvironment in humans

Focussed Research Review

Designing therapeutic cancer vaccines by mimicking viral infections

Focussed Research Review

Using natural products to promote caspase-8-dependent cancer cell death

Original Article

Cytokine-induced killer cells hunt individual cancer cells in droves in a mouse model

Original Article

Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells

Original Article

Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits